Nuvectis Pharma delays listing as IPO market turns cautious
font size
dream time
The IPO market remains paused as the only week’s offering has been postponed.
Novictis Pharma It was scheduled It is scheduled to open for trading Wednesday but has opted to delay its initial public offering, a person familiar with the situation said. Nuvectis did not immediately respond with messages for comment.
Nuvectis, which develops drugs to treat cancer, was the only company due to be listed this week. Biotechnology I planned to show 2.3 million shares at $12 to $14 per share. ThinkEquity is the guarantor. No company opened for trading last week using a traditional IPO due to the Thanksgiving holiday.
Nuvectis is the latest company to delay its offering. KinderCare Learning Companies, a child care center operator, decided in November not to go ahead with the IPO, Baron mentioned. DailyMobil Holdings, a Russian car sharing companyand oil company Desert Peak Minerals, both chose to delay their deals last month, according to Matt Kennedy, chief IPO strategist at Renaissance Capital. Delimobil and Desert Peak did not immediately respond with messages for comment.
Nubank, the Brazilian digital lender, IPO valuation also lowered On Tuesday, about $10 billion. Kennedy said this indicates that IPO investors are getting more cautious in addition to their deal-specific concerns about the Brazilian economy.
“In the fourth quarter, we saw a number of postponements,” Kennedy said. He said IPO returns “have been volatile lately, including a sharp drop in the IPO market.” In November, less than half of the 34-month traditional initial public offering (IPO) traded above the offer price, Renaissance said.
The
Renaissance for public offering
Kennedy added that exchange-traded funds (IPOs), which track companies for three years after they go public, fell 8% in November and are nearly negative for the year.
The IPO market is still on track for a big public release. So far in 2021, DeLogic said, 943 companies have gone public as of November 30, raising about $299 billion. Most or 60% of 943 IPOs are special purpose acquisitions. The rest, or 383, are traditional IPOs.
December can be a busy time of new issues as companies look to bring them to the public before the Christmas holidays. The IPO market is usually closed from Christmas to mid-January. Two big deals are scheduled to open next week.
Nubank, backed by Warren Buffett Berkshire Hathaway (BRK.B), plans to offer approximately 289.2 million shares at $8 to $9 per share, Bulletin said. This is lower than its previous range From $10 to $11. At $9 a share, Nubank could have a valuation of nearly $41.5 billion, making it one of the biggest IPOs of the year. Morgan Stanley, Goldman SachsAnd City Group, and NuInvest are the main underwriters in the IPO.
HashiCorp, a cloud software provider, is also scheduled to be listed during the first full week of December. company Offering 15.3 million shares at $68 to $72 per share. At $72, HashiCorp is targeting a valuation of $13 billion. Morgan Stanley, Goldman Sachs And JPMorgan are the two main underwriters in the deal.
Kennedy said HashiCorp is a fast-growing, high-margin software company that typically does very well in the IPO market. “But if it doesn’t, that’s a big sign that the IPO market is getting more cautious, because so far the best-in-class, high-growth companies have been doing very well even if other IPOs have generated less interest.”
Write to Luisa Beltran at luisa.beltran@dowjones.com
.